International Stem Cell recently announced that the first cohort of four patients in its Phase I trial in Parkinson’s disease (PD) had successfully undergone intracranial transplants of ISC-hpNSC. The study will ultimately enroll 12 patients at three dosing regimens (30m-70m cells) with a primary endpoint of safety, but will provide preliminary efficacy data measured at six and 12 months following the treatment.
27 Apr 2017
Dosing of first cohort complete
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Dosing of first cohort complete
- Published:
27 Apr 2017 -
Author:
Maxim Jacobs -
Pages:
5
International Stem Cell recently announced that the first cohort of four patients in its Phase I trial in Parkinson’s disease (PD) had successfully undergone intracranial transplants of ISC-hpNSC. The study will ultimately enroll 12 patients at three dosing regimens (30m-70m cells) with a primary endpoint of safety, but will provide preliminary efficacy data measured at six and 12 months following the treatment.